DUBLIN, Feb. 1, 2024 /PRNewswire/ --

EMA Aesthetics (www.emaaesthetics.com) a global aesthetics company headquartered in Dublin, is delighted to announce a strategic and equity partnership with ROHTO Pharmaceutical (www.rohto.co.jp/global), a renowned Japanese multinational known for innovative approaches in healthcare and skincare and its European affiliate Rohto Mediluxe Europe.

EMA Aesthetics & Rohto Logos

This strategic alliance signals ROHTO's acceleration into the medical aesthetics sector, supporting the growth of EMA Aesthetics in a rapidly expanding global market. EMA and ROHTO will employ R&D and collaboration to jointly develop existing and novel aesthetic products. This partnership provides ROHTO with a gateway into the aesthetics industry beyond Japan, emphasizing their commitment to harness the notable expansion in the aesthetics sectors within the EU and US, into 2024 and beyond.

Malcolm Wall Morris, Co-Founder and CEO of EMA Aesthetics, remarked, "Since its inception in 2019, EMA Aesthetics has consistently been a pioneer in aesthetic products. Our philosophy of continual innovation, driven by our dedication to surpass industry norms and exceed stakeholders' expectations, has been pivotal in our journey. The partnership with ROHTO signifies a key moment in our trajectory.  Jointly, we are poised to push the limits of aesthetic products, enhancing our worldwide presence and reiterating our commitment to excellence and innovation."

Nobuhiro Hirasawa, CEO of ROHTO Mediluxe Europe (Rohto MLE), a representative of medical aesthetic business in EMEA on behalf of ROHTO Pharmaceutical, added, "I am delighted to confirm our involvement in this thrilling venture as ROHTO embarks on an exciting partnership at its 125th anniversary year. This collaboration signifies a fusion, where the disruptive innovation of EMA converges with ROHTO's steadfast customer orientation. It's a harmonious blend where EMA's cutting-edge device technology aligns seamlessly with ROHTO's robust research and development.  I am confident that this partnership will pave the way for excellence in value creation. Above all, I eagerly anticipate the gratifying experience of working with both teams."

The investment not only reinforces ROHTO's position in EMEA but also broadens its reach into the US and other markets. EMA alongside ROHTO will focus on creating products to deliver great patient results and an enhanced user experience for clinics and therapists.

The global aesthetic medicine sector is leading the beauty and personal care products market's rapid growth, which is in excess of $500 billion in 2022. This sector is expected to see a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030. APAC holds a dominant revenue share of 39% and is anticipated to experience rapid growth.

About EMA Aesthetics

EMA Aesthetics, founded in 2019 and headquartered in Ireland, is an international company which specialises in the development and creation of advanced skincare technology, focused on combination therapy, that enhance non-invasive aesthetic procedures, providing professional aesthetic products and services. EMA Aesthetics has offices in Ireland, Belgium and the United Arab Emirates with a sales network which covers 30 countries and regions around the world.

Contact: [email protected]
For more information, visit : www.emaaesthetics.com/ 

About ROHTO Pharmaceutical 

Founded in 1899 and headquartered in Osaka (Japan), Rohto Pharmaceutical Co., Ltd. (ROHTO) is a world-multinational producer and supplier of consumer goods, pharmaceuticals and skincare products.  ROHTO has expanded its business to more than 110 countries until today and is aiming to deliver well-being worldwide in pursuit of a sustainable society where people can enjoy longer, healthier, and happier lives.

Contact: [email protected]
For more information, visit  www.rohto.co.jp/global

Media Contacts:
EMA Aesthetics Ltd.
Tel: +971 4 383 6708
[email protected]